Evolution of the Average Target: NOV Inc.

Data source: NOV Inc.(NOV)
Evolution of the Average Target - NOV Inc.

Evolution of the Target Price: NOV Inc.

Data source: NOV Inc.(NOV)
Evolution of the Target Price - NOV Inc.

Changes in Analyst Recommendations: NOV Inc.

Data source: NOV Inc.(NOV)
3f677cad90ac3b298d80a00e.17dnp-Grc8MowAKv5CYii7Vo2KMjRujCTMsRhg5zvA0.m_AsktHYLJN7tVfVj2lS5IZQtOZ1dLG4L4hj83w86F2GwTaKoNhLsWmmNg~77ad354dd6c120fd689f98c8a3748a01
06-04 NOV Shares Rise After Capital One Upgrade MT
06-04 Capital One Upgrades NOV to Overweight From Equal Weight, Adjusts Price Target to $26 From $25 MT
04-30 Zephirin Cuts Price Target on NOV to $17 From $18, Keeps Hold Rating, Medium Risk MT
04-29 RBC Lifts Price Target on NOV to $22 From $21, Keeps Sector Perform Rating MT
04-14 NOV Offers Upside From Improved Offshore and Short-Cycle Activity but Better Alternatives Exist, RBC Says MT
04-14 RBC Downgrades NOV to Sector Perform From Outperform, Keeps $21 Price Target MT
04-14 Analyst recommendations: Biogen, Ford, Ge Vernova, Booking, Comcast… Zonebourse
02-23 Zephirin Downgrades NOV to Hold From Buy, Lifts Price Target to $18 From $17, Keeps Medium Risk MT
02-12 Analyst recommendations: Pfizer, Applovin, Biogen, Hilton, Snap… Zonebourse
02-04 Barclays Upgrades NOV to Equalweight From Underweight, Raises Price Target to $20 From $15 MT
02-04 Analyst recommendations: Booking, PayPal, Fedex, Gartner, Lockheed Martin…. Zonebourse
01-15 RBC Capital Adjusts NOV Price Target to $21 From $19, Maintains Outperform Rating MT
01-14 Analyst recommendations: Rivian, Applied Materials, Coinbase, Intel, Spotify… Zonebourse
11-20 Zephirin Lowers Price Target on NOV to $16 From $17, Keeps Buy Rating MT
25-10-29 RBC Raises Price Target on NOV to $19 From $17, Keeps Outperform Rating MT
25-10-09 RBC Lowers Price Target on NOV to $17 From $18, Keeps Outperform Rating MT
25-07-30 RBC Cuts Price Target on NOV to $18 From $19, Keeps Outperform Rating MT
25-07-28 NOV's Q2 revenue falls but beats expectations RE
25-05-15 Zephirin Cuts Price Target on NOV to $17 From $19, Keeps Buy Rating MT
25-04-30 RBC Trims Price Target on NOV to $19 From $20, Keeps Outperform Rating MT
25-03-24 Analyst recommendations: General Mills, Ulta Beauty, Micron Technology, RH… Zonebourse
25-03-24 RBC Upgrades NOV to Outperform From Sector Perform, Maintains $22 Price Target MT
25-02-06 RBC Raises Price Target on NOV to $22 From $21, Keeps Sector Perform Rating MT
25-01-15 Evercore ISI Downgrades NOV to In Line From Outperform, Adjusts Price Target to $18 From $25 MT
25-01-06 Seaport Downgrades NOV to Neutral From Buy MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+28.05%
+26.07%
+9%
+8.3%
+32.36%
+103.42%
+7.22%
+6.63%
+16.73%
Average +26.42%
Weighted average by Cap. +26.10%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
18.96USD
Average target price
22.13USD
Spread / Average Target
+16.73%
High Price Target
26.00USD
Spread / Highest target
+37.13%
Low Price Target
17.00USD
Spread / Lowest Target
-10.34%

Analyst Consensus Detail

Analyst consensus - NOV Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - NOV Inc.
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - NOV Inc.